Randomized Trialhigh evidence
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
Lancet (London, England)·December 6, 2025·PMID 41207310
Why it mattersAmylin receptor agonists represent a novel mechanism for obesity pharmacotherapy. Eloralintide’s substantial weight loss in a phase 2 trial suggests it could become an important option, especially for patients who do not tolerate or respond adequately to GLP-1-based treatments.

The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled